Abetalipoproteinemia (ABL) is a rare autosomal recessive disorder marked by low or absent levels of plasma cholesterol, low-density lipoproteins (LDLs), and very-low-density lipoproteins (VLDLs). It should not be confused with a deficiency in beta-lipoproteins. Hallmark symptoms include fat malabsorption, spinocerebellar degeneration, acanthocyte red blood cells, and retinitis pigmentosa. ,
Treatment aims to arrest the neuropathy and efficiency-induced complications in patients.
Abetalipoproteinemia is caused by a homozygous autosomal recessive mutation in the MTTP gene. More than 33 mutations that cause the disease have been identified. The gene codes for microsomal triglyceride protein (MTP) that mediates intracellular chylomicron or VLDL assembly and transport in the intestinal mucosa and hepatocytes. Most of the signs and symptoms of the disease result from a severe deficiency of fats and fat-soluble vitamins, especially vitamin E. It usually presents in infants as failure to thrive, steatorrhea, and abdominal distension and results in spinocerebellar degeneration and retinitis pigmentosa.
Abetalipoproteinemia occurs in less than 1 in 1 million persons. Consanguineous marriages are strongly implicated. Because it is autosomal recessive, both copies of the gene must be faulty to cause the disease. It occurs in females and males equally. 
One particular mutation is more common in people of Ashkenazi (eastern and central European) Jewish descent. This mutation substitutes the protein building block, or amino acid, glycine with a stop signal at position 865 (written as Gly865X or G865X). As a result of this amino acid change, an abnormally small, nonfunctional version of the protein is made. 
Beta apolipoproteins are very large apolipoproteins. They are critically important for the secretion and formation of chylomicrons (CMs) and VLDL. Abnormalities that impede this process result in abetalipoproteinemia and hypobetalipoproteinemia. ,,
MTP acts as a chaperone that facilitates the transfer of lipids onto apo B. MTP is found within the lumen of microsomes in the liver and intestinal mucosa and catalyzes the transfer of triglyceride, cholesteryl esters, and phosphatidylcholine between membranes. Lipid transport rates decrease in the order of triglyceride to cholesteryl ester to diglyceride to cholesterol to phosphatidylcholine. Unlike other lipid transfer proteins, MTP is a heterodimer containing subunits of molecular mass 58 and 97 kDa. The large 97-kDa subunit possesses the lipid transfer activity or confers lipid transfer activity on the complex. The large subunit of MTP may be missing in abetalipoproteinemia.
Initial assembly occurs in the endoplasmic reticulum where apolipoproteins, cholesterol, phospholipid, and triacylglycerides are synthesized and incorporated into lipoprotein particles. The particles are subsequently transported to Golgi and secreted. Each lipoprotein is specific in its lipid composition and type of apolipoproteins it possesses.
The two beta apolipoproteins are B-100 and B-48. ApoB-100 is carried on VLDL. ApoB-100, synthesized by the liver, is larger than apoB-48, which is made up of 4536 amino acids. Unlike apoB-48, apoB-100 contains the binding site essential for LDL uptake by hepatocyte LDL receptors. ApoB-48 is carried on CMs, is derived from the same gene as apoB-100. 
These manifestations include diarrhea and fat-soluble vitamin deficiency. They are evident from infancy. Diarrhea may not be a prominent symptom later though because patients learn to avoid fatty foods. However, the deficits in fat-soluble vitamins continue, because their assimilation and transport depend heavily on the integrity of the apoB pathway. It is worth noting that high dose vitamin-E supplementation only results in marginally increased serum vitamin levels. In contrast, high doses of vitamin-A therapy can achieve normal serum levels. This shows that despite the damaged intestinal absorption, the transport of vitamin A by retinol-binding proteins in serum is not impaired in abetalipoproteinemia.
Acanthocytosis is a hallmark feature of this disease. Acanthocytes are abnormally spiked RBCs due to the defective phospholipid cell membrane. They are also seen in liver dysfunction. Because of their inability to form rouleaux, erythrocyte sedimentation rates could be very low. Fat malabsorption could lead to deficiencies in iron, folic acid, among others and lead to anemia. Vitamin E is involved in protection from free radical damage. Its deficiency could potentiate lipid peroxidation of cells and lead to hemolysis. This exacerbates anemia. Vitamin K is involved in the gamma decarboxylation of clotting factors, an indispensable step in coagulation. Its deficiency could lead to bleeding disorders.
Peripheral neuropathy, delayed intellectual development, tremor, nystagmus, loss of deep tendon reflexes
These may be myriad and variable in their severity. The primary pathophysiology is demyelination due to deficiency of lipid-soluble vitamins. The central and peripheral nervous systems are both affected.
Weakness and increased degeneration
Retinitis pigmentosa, decreased night and color vision, blindness
Acanthocytes on the peripheral blood smear are pathognomonic for abetalipoproteinemia.
Failure to thrive in infancy may cause gastroenterologic, neurologic, and ophthalmologic symptoms, including the following:
Complete Blood Count
Complete blood count shows anemia, thrombocytopenia, or pancytopenia.
Blood smear shows acanthocytes (Burr cells).
Fasting Lipid Profile
Fasting lipid profile shows low VLDLs, LDLs, and total cholesterol.
Stool studies show fat malabsorption and absence of evidence for other possible causes.
Abetalipoproteinemia is a relatively rare genetic and acquired disorder that is characterized by acanthocytic red blood cells, fat malabsorption, spinocerebellar degeneration and pigmented retinopathy. The condition is associated with very high morbidity and thus it is vital to have an integrated pathway of management with close interaction with a number of health professionals. Besides a gastroenterologist, an interprofessional approach is essential if one is to improve outcomes:
Because of the rarity of the disorder, there is a lack of randomized clinical trials on the long-term benefits of vitamins. However, small case series and anecdotal reports indicate that when patients are diagnosed and referred early to a clinic which specializes in the management of this lipid disorder, the outcomes are improved. There is ample evidence indicating that prompt supplementation with vitamins can improve the prognosis and outcome. (Level III) However, the long-term outlook for many of these patients is guarded as many go on to develop vision loss and permanent blindness.